Biomednewsbreaks - Kairos Pharma Ltd. (NYSE American: KAPA) Publishes Findings On Overcoming NSCLC Drug Resistance

(MENAFN- Investor Brand Network) Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharmaceutical company, has published a peer-reviewed study highlighting a potential breakthrough in addressing drug resistance to EGFR-targeted therapies for non-small cell lung cancer (NSCLC). The study, published in Drug Resistance Updates, identifies CD105 (endoglin) as a key factor in mediating resistance to osimertinib, a frontline treatment for EGFR-mutant NSCLC. Preclinical models demonstrated that targeting CD105 with ENV105 (carotuximab), a CD105-neutralizing antibody, restored treatment sensitivity, suggesting a novel combination therapy strategy to overcome drug resistance. Kairos Pharma is currently evaluating this approach in clinical trials.

To view the full press release, visit

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate, ENV105, is an antibody that targets CD105-a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit the company's website at .

NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company's newsroom at

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
Austin, Texas

512.354.7000 Office
[email protected]

BioMedWire is powered by IBN

MENAFN20032025000224011066ID1109338824